基本信息 产品详情 公司简介 推荐产品
网站主页 3-[1-(3-氨基丙基)-1H-吲哚-3-基]-4-(1-甲基-1H-吲哚-3-基)-1H-吡咯-2,5-二酮单乙酸盐 化合物 Bisindolylmaleimide VIII acetate
  • 化合物 Bisindolylmaleimide VIII acetate|T10549|TargetMol

化合物 Bisindolylmaleimide VIII acetate|T10549|TargetMol

Bisindolylmaleimide VIII acetate
138516-31-1
391 1mg 起订
954 5mg 起订
1480 10mg 起订
上海 更新日期:2024-09-29

TargetMol中国(陶术生物)

VIP3年
联系人:邵小姐
手机:4008200310 拨打
邮箱:marketing@tsbiochem.com

产品详情:

中文名称:
化合物 Bisindolylmaleimide VIII acetate
英文名称:
Bisindolylmaleimide VIII acetate
CAS号:
138516-31-1
品牌:
TargetMol
产地:
美国
保存条件:
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
纯度规格:
99.27%
产品类别:
抑制剂
货号:
T10549

Product Introduction

Bioactivity

NameBisindolylmaleimide VIII acetate
DescriptionBisindolylmaleimide VIII acetate (Ro 31-7549 acetate) is a potent and selective PKC inhibitor (IC50: 158 nM for rat brain PKC). It has IC50s of 53, 195, 163, 213, and 175 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, PKC-ε, respectively.
In vitroBisindolylmaleimide VIII acetate facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases. Bisindolylmaleimide VIII acetate (5 μM; 8, 12 hours) dramatically increases TRA-8-induced cell death in time-dependent and TRA-8 dose-dependent manners. Bisindolylmaleimide VIII acetate (5 μM; 6 hours) significantly decreases procaspase-8 at 4 h and completely disappears at 6 h after the combined treatment with TRA-8 [2].
In vivoBisindolylmaleimide VIII acetate (100 μg; i.p.; every other day for three doses) results in nearly complete tumor regression combined toTRA-8. The alone treatment with Bisindolylmaleimide VIII acetate does not induce significant tumor regression [2].
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility InformationDMSO : 55 mg/ml (119.95 mM)
Keywordsprotein | Bisindolylmaleimide VIII acetate | Ro 31-7549 | Inhibitor | inhibit | Ro 31-7549 Acetate | Fas | Bis VIII | Apoptosis | autoimmune | Protein kinase C | diseases | kinase | cell-mediated | Bisindolylmaleimide VIII | Bisindolylmaleimide VIII Acetate | Bis VIII Acetate | PKC
Inhibitors RelatedLidocaine hydrochloride | Metronidazole | 5-Fluorouracil | Stavudine | Tributyrin | Dextran sulfate sodium salt (MW 4500-5500) | Myricetin | Sorafenib | L-Ascorbic acid | Acetylcysteine | Sodium 4-phenylbutyrate | Kaempferol
Related Compound LibrariesInhibitor Library | Bioactive Compound Library | Bioactive Compounds Library Max | Kinase Inhibitor Library | Apoptosis Compound Library | Cytoskeletal Signaling Pathway Compound Library | NO PAINS Compound Library | Epigenetics Compound Library | TGF-beta/Smad Compound Library | Reprogramming Compound Library
Ro 31-7549 acetate|||Bis VIII acetate|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿,致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区,已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库,以及多种类型的生化试剂产品,包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等,此外,我们还建设有CADD(计算机辅助药物设计)研究中心、药理实验室、药化合成平台三大技术中心,全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持,我们将有效帮助您缩短研发周期,取得更成功的结果。

成立日期 (12年)
注册资本 566.265100万人民币
员工人数 100-500人
年营业额 ¥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

化合物 Bisindolylmaleimide VIII acetate相关厂家报价

内容声明
拨打电话 立即询价